ClearPoint Neuro (NASDAQ:CLPT) Stock Rating Lowered by Wall Street Zen

ClearPoint Neuro (NASDAQ:CLPT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other research firms also recently issued reports on CLPT. Stifel Nicolaus increased their target price on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, ClearPoint Neuro has an average rating of “Moderate Buy” and an average price target of $19.67.

ClearPoint Neuro Trading Down 0.5%

Shares of NASDAQ CLPT opened at $15.43 on Friday. The company has a current ratio of 7.30, a quick ratio of 6.45 and a debt-to-equity ratio of 1.46. ClearPoint Neuro has a one year low of $9.76 and a one year high of $30.10. The business has a 50-day moving average price of $19.89 and a two-hundred day moving average price of $14.61. The firm has a market capitalization of $438.57 million, a PE ratio of -19.05 and a beta of 1.28.

ClearPoint Neuro (NASDAQ:CLPT) last issued its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The business had revenue of $5.36 million during the quarter, compared to analyst estimates of $9.60 million. ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. ClearPoint Neuro has set its FY 2025 guidance at EPS. As a group, analysts predict that ClearPoint Neuro will post -0.66 earnings per share for the current fiscal year.

Insider Buying and Selling at ClearPoint Neuro

In related news, CEO Joseph Burnett sold 26,463 shares of the firm’s stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $26.98, for a total value of $713,971.74. Following the transaction, the chief executive officer directly owned 217,059 shares of the company’s stock, valued at approximately $5,856,251.82. This trade represents a 10.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On ClearPoint Neuro

A number of institutional investors have recently modified their holdings of the company. Allworth Financial LP boosted its holdings in shares of ClearPoint Neuro by 3,076.9% during the 2nd quarter. Allworth Financial LP now owns 2,065 shares of the company’s stock worth $25,000 after buying an additional 2,000 shares during the period. BNP Paribas Financial Markets boosted its holdings in ClearPoint Neuro by 2,435.2% during the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after acquiring an additional 2,143 shares during the period. Financial Management Professionals Inc. acquired a new stake in shares of ClearPoint Neuro in the third quarter valued at about $28,000. Ameritas Investment Partners Inc. bought a new position in shares of ClearPoint Neuro in the second quarter worth about $32,000. Finally, Legal & General Group Plc bought a new position in shares of ClearPoint Neuro in the second quarter worth about $35,000. Institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.